Drawing for TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

USPTO serial 97769288

TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
LOBO, DEBORAH E
Law office
TMEG LAW OFFICE 109 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with TUMOR-DIRECTED ONCOLYTIC IMMUNOTHERAPIES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Melanie Howard

MELANIE HOWARD LOEB & LOEB LLP10100 SANTA MONICA BOULEVARD, SUITE 2200LOS ANGELES, CA 90067UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations; viruses; viruses for the treatment of disease; viruses for the treatment of cancer; viruses for inducing immune response; pharmaceuticals; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response; vaccines; immunotherapy products; gene therapy products; Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disordersACTIVE—
042Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaidACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Feb 16, 2024MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Feb 16, 2024ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 2, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 2, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 2, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 24, 2023DOCKASSIGNED TO EXAMINER—
Feb 15, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 30, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance